Gain valuable insights and knowledge through our free on-demand webinar

First Name
Last Name
Are you a YourEncore Expert or interested in becoming one?
Thank you!
Error - something went wrong!

[WEBINAR] 9 Biotech Valuation Killers

August 23, 2016


9 Biotech Valuation Killers: Preparing for Large Pharma Due Diligence

Presenters: Brian Daniels, M.D. and Don Therasse, M.D.

According to a global study by Mergermarket and Reed Smith, 94 percent of senior life sciences executives plan to make an acquisition in 2016, so biotech firms need to do everything possible to make sure they are properly positioned to get the most value for their asset.

To help maximize the valuation of their assets and attract more suitors, YourEncore has assembled distinguished panelists, Dr. Brian Daniels, former SVP of Global Development for Bristol-Myers Squibb, and Dr. Don Therasse, former VP of Global Patient Safety and Medical Affairs for Eli Lilly & Company, to share their best advice from evaluating hundreds of assets throughout their careers.

The first rule is to do good science. This is a given. After that, follow the nine rules to maximize valuations,which Drs. Daniels and Therasse will present in the upcoming webinar.

About Brian Daniels, M.D.Brian Daniels is a Strategic Advisor for YourEncore specializing in clinical development and commercialization. He is the former senior vice president, global development and medical affairs at Bristol-Myers Squibb.  

About Don Therasse, M.D.: Don Therasse is a Strategic Advisor for YourEncore specializing in clinical development, medical affairs and drug safety. He is the former vice president, global patient safety and global medical affairs at Eli Lilly and Company.

Previous Article
FDA 483 Response: Four Tips to Avoid a Warning Letter
FDA 483 Response: Four Tips to Avoid a Warning Letter

The receipt of a 483 at the conclusion of a facility inspection notifies a company of conditions...

Next Article
Embracing Satan's PDUFA
Embracing Satan's PDUFA

Monday’s public meeting on the FDA’s PDUFA VI Commitment Letter was a love-fest (mostly) – but a...